Enlaza Therapeutics, a La Jolla, CA-based covalent biologic company, raised $61M in Seed financing.
The round was led by Avalon Ventures, with participation from Lightspeed Venture Partners, Frazier Life Sciences, and Samsara BioCapital.
The company intends to use the funds to advance its proprietary War-Lock platform and build a pipeline of covalent biologics with an initial focus on developing novel, differentiated cancer therapeutics with targeted efficacy and low toxicity.
Led by CEO Sergio Duron, Enlaza Therapeutics leverages a covalent biologic platform which creates specific therapeutic warheads that lock onto targets of interest, producing broadly applicable therapeutic candidates with drug-like properties.
Enlaza’s War-Lock platform is based on technologies exclusively licensed from UCSF, negotiated through UCSF’s Innovation Ventures’ Office of Technology Management & Advancement, which leads licensing and business development efforts on behalf of the University, and The Scripps Research Institute.